Date published: 2025-12-8

1-800-457-3801

SCBT Portrait Logo
Seach Input

MEK-7 Inhibitors

MEK-7 inhibitors represent a class of chemicals designed to selectively target and impede the activity of MEK1 and MEK2, crucial components of the mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway plays a pivotal role in transducing extracellular signals to the nucleus, regulating cellular processes such as proliferation, differentiation, and survival. These inhibitors, including Selumetinib, PD0325901, Trametinib, Cobimetinib, Binimetinib, Refametinib, Pimasertib, MEK162, TAK-733, AZD8330, GDC-0623, and RO5126766, share a common mechanism of action by disrupting MEK-mediated phosphorylation of ERK1/2. Selumetinib, for instance, distinguishes itself with high specificity for MEK, minimizing off-target effects and providing a focused intervention. PD0325901, Cobimetinib, and Binimetinib, among others, contribute to cancer therapy by precisely targeting MEK1 and MEK2, stopping the downstream activation of ERK1/2 and thereby hindering uncontrolled cell growth. These inhibitors exhibit significant promise in modulating aberrant MAPK signaling, a hallmark of tumorigenesis in various malignancies. The specificity of these MEK-7 inhibitors is crucial in avoiding non-specific interference with other cellular processes.The detailed understanding of each inhibitor's specificity allows for a tailored approach to attenuate dysregulated MAPK signaling. Overall, MEK-7 inhibitors stand at the forefront of molecular interventions.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$28.00
$80.00
$412.00
$1860.00
$2962.00
5
(1)

Selumetinib is a potent and selective inhibitor of MEK1/2, impeding the MAPK signaling pathway. By targeting MEK, it disrupts the downstream activation of ERK1/2, hindering the transmission of proliferative signals.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib, a highly selective MEK inhibitor, modulates the MAPK pathway by impeding MEK1/2-mediated phosphorylation of ERK1/2. This disruption curtails downstream signaling, attenuating cellular processes associated with proliferation.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

Cobimetinib acts as a potent MEK inhibitor, specifically targeting MEK1 and MEK2. By impeding MEK-mediated activation of ERK1/2, it disrupts the MAPK pathway, thereby hindering cellular processes linked to proliferation.

BAY 869766

923032-37-5sc-364427
sc-364427A
5 mg
10 mg
$240.00
$420.00
1
(1)

BAY 869766, a selective MEK inhibitor, disrupts the MAPK pathway by targeting MEK1 and MEK2. By inhibiting MEK-mediated phosphorylation of ERK1/2, it hampers downstream signaling events essential for cell survival and proliferation.

AS703026

1236699-92-5sc-364412
sc-364412A
5 mg
10 mg
$80.00
$130.00
(0)

AS703026 (Pimasertib) functions as a MEK inhibitor, specifically targeting MEK1 and MEK2. By inhibiting MEK-mediated phosphorylation of ERK1/2, it disrupts the MAPK pathway, hindering downstream signaling events crucial for cell proliferation.

MEK 162

606143-89-9sc-488879
10 mg
$306.00
(0)

MEK162, a potent MEK inhibitor, disrupts the MAPK pathway by specifically targeting MEK1 and MEK2. By inhibiting MEK-mediated phosphorylation of ERK1/2, it hampers downstream signaling events essential for cell survival and proliferation.

TAK-733

1035555-63-5sc-364630
sc-364630A
5 mg
10 mg
$340.00
$640.00
1
(0)

TAK-733 acts as a MEK inhibitor, specifically targeting MEK1 and MEK2. By inhibiting MEK-mediated phosphorylation of ERK1/2, it disrupts the MAPK pathway, hindering downstream signaling events crucial for cell proliferation.

AZD8330

869357-68-6sc-364425
sc-364425A
5 mg
10 mg
$255.00
$450.00
(0)

AZD8330 serves as a MEK inhibitor, acting specifically on MEK1 and MEK2. By impeding MEK-mediated phosphorylation of ERK1/2, it disrupts the MAPK pathway, thereby hindering cellular processes associated with proliferation.